<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 14, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509661</url>
  </required_header>
  <id_info>
    <org_study_id>20200413</org_study_id>
    <nct_id>NCT04509661</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation</brief_title>
  <official_title>Efficacy and Safety of Inhaled Bronchodilator in Non-cystic Fibrosis Bronchiectasis Patients With Airflow Limitation: a Multicenter, Open-label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Airflow limitation is common exist in idiopathic bronchiectasis patients. However, there are&#xD;
      few evidence on the treatment of bronchodilator in bronchiectasis with airflow limitation.&#xD;
      The efficacy and safety of dual bronchodilator in idiopathic bronchiectasis with airflow&#xD;
      limitation are still unclear. Thus, the investigators conduct a multicenter, open-label&#xD;
      randomized controlled trial to investigate the efficacy and safety of dual bronchodilator in&#xD;
      idiopathic bronchiectasis with airflow limitation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Airflow limitation is common exist in idiopathic bronchiectasis patients. Our previous&#xD;
      studies showed that FEV1&lt;50% is one of the major risk factors for poor prognosis and high&#xD;
      incidence of acute exacerbation in patients with bronchiectasis. However, there are few&#xD;
      evidence on the treatment of bronchodilator in bronchiectasis with airflow limitation, and&#xD;
      there is no recommendation in bronchiectasis guidelines. Moreover, because of the high risk&#xD;
      of infection and bacterial colonization in bronchiectasis, there is still unclear whether&#xD;
      inhaled corticosteroids or bronchodilators affect the parameters of bronchiectasis. Thus,&#xD;
      there is urgent need to optimize the treatment of bronchiectasis with airflow limitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actue exacerbation</measure>
    <time_frame>One year</time_frame>
    <description>Times of acute exacerbation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified Medical Research Council score</measure>
    <time_frame>Six months</time_frame>
    <description>modified Medical Research Council score for the degree of dyspnea. The minimum value is 0 and maximum value is 4. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leicester Cough Questionnaire</measure>
    <time_frame>Six months</time_frame>
    <description>Cough Questionnaire for the degree of cough. The minimum value is 1 and maximum value is 21. Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire of life-Bronchiectasis</measure>
    <time_frame>Six months</time_frame>
    <description>Including eight scales: respiratory symptoms; physical, role, emotional, and social functioning; vitality; health perceptions; and treatment burden. For each scale, scores are standardized on a 0-to-100-point scale; higher scores indicate better health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1, FVC</measure>
    <time_frame>Six months</time_frame>
    <description>Forced Expiratory Volume In 1s and Forced Vital Capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1%</measure>
    <time_frame>Six months</time_frame>
    <description>The percent of predicted Forced Expiratory Volume In 1s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of atrial fibrillation</measure>
    <time_frame>Six months</time_frame>
    <description>One of common adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of coronary artery disease</measure>
    <time_frame>Six months</time_frame>
    <description>One of common adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bronchiectasis Adult</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol-Glycopyrronium (110ug/50ug QD inhalation) for one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment for the airway limitation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABA/LAMA or Placebo inhalation</intervention_name>
    <description>Inhaled LABA/LAMA for one year.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Inhaled dual Bronchodilator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic bronchiectasis with FEV1/FVC &lt; 70%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With Asthma&#xD;
&#xD;
          -  Î±-1 antitrypsin deficiency&#xD;
&#xD;
          -  Turculosis&#xD;
&#xD;
          -  Lung cancer&#xD;
&#xD;
          -  Sarcoidosis&#xD;
&#xD;
          -  Idiopathic pulmonary fibrosis&#xD;
&#xD;
          -  Primary pulmonary hypertension&#xD;
&#xD;
          -  Uncontrolled sleep apnea&#xD;
&#xD;
          -  Bronchiectasis accepted long-term low dose macrolides&#xD;
&#xD;
          -  Pulmonary surgery within 6 months&#xD;
&#xD;
          -  Lower respiratory tract infections require antibiotic treatment in 6 weeks&#xD;
&#xD;
          -  Upper respiratory tract infection did not recover for at least 7 days&#xD;
&#xD;
          -  With Glaucoma or severe prostate hyperplasia that can not use Indacaterol&#xD;
&#xD;
          -  Patients allergic to experimental drugs&#xD;
&#xD;
          -  Women pregnant, breast-feeding or who planned a pregnancy during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-fu Xu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-fu Xu, MD</last_name>
    <phone>+86 13321922898</phone>
    <email>jfxucn@163.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Jin-Fu Xu</investigator_full_name>
    <investigator_title>Chief of Department of Pulmonary and Critical Care Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

